Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult pati…
HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – ...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...
clinicalpainadvisor.com9d
Steroid Injection Plus Oral Steroid Best for Preventing Esophageal Stricture After ESD
Steroid injection combined with oral steroid therapy outperformed other steroid administrations for preventing esophageal stricture post-ESD.
T-Net2d
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...
EurekAlert!11d
Neuromodulation for gastroesophageal reflux disease
Gastroesophageal reflux disease (GERD) is a prevalent chronic condition characterized by recurrent reflux of stomach contents into the esophagus, leading to troublesome symptoms such as heartburn, ...
Global trial ends 20-year debate over gastro-esophageal cancer treatment
Cancer patients could avoid unnecessary radiation therapy as a result of an international clinical trial, led by Peter Mac ...
Medindia1d
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...
Medscape2d
New Endoscopic Method for GERD Diagnosis Shows High Accuracy
This test is particularly valuable when endoscopy doesn't reveal esophagitis yet patients continue to experience refractory ...
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...
Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...
Medindia15h
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES-  SCLC   - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 ...